Literature DB >> 27177201

Assessment of different 3D culture systems to study tumor phenotype and chemosensitivity in pancreatic ductal adenocarcinoma.

Katrine Zeeberg1, Rosa Angela Cardone1, Maria Raffaella Greco1, Mara Saccomano2, Asbjørn Nøhr-Nielsen3, Frauke Alves2, Stine Falsig Pedersen3, Stephan Joel Reshkin1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant disease with a very poor prognosis, due to the influence of the tumor stroma, which promotes tumor growth, early invasion and chemoradiation resistance. Efforts to develop models for identifying novel anticancer therapeutic compounds have been hampered by the limited ability of in vitro models to mimic these in vivo tumor-stroma interactions. This has led to the development of various three-dimensional (3D) culture platforms recapitulating the in vivo tumor-stroma crosstalk and designed to better understand basic cancer processes and screen drug action. However, a consensus for different experimental 3D platforms is still missing in PDAC. We compared four PDAC cell lines of different malignancy grown in 2D monolayers to three of the more commonly used 3D techniques (ultralow adhesion concave microwells, Matrigel inclusion and organotypic systems) and to tumors derived from their orthotopic implantation in mice. In these 3D platforms, we observed that cells grow with very different tumor morphologies and the organotypic setting most closely resembles the tumor cytoarchitecture obtained by orthotopically implanting the four cell lines in mice. We then analyzed the molecular and cellular responses of one of these cell lines to epidermal growth factor receptor (EGFR) stimulation with EGF and inhibition with erlotinib and found that only in the 3D platforms, and especially the organotypic, cells: i) responded to EGF by changing the expression of signalling components underlying cell-stroma crosstalk and tissue architecture, growth, invasion and drug resistance (E-cadherin, EGFR, ezrin, β1 integrin, NHERF1 and HIF-1α) similar to those reported in vivo; ii) had stimulated growth and increased erlotinib sensitivity in response to EGF, more faithfully mimicking their known in vivo behaviour. Altogether, these results, indicate the organotypic as the most relevant physiological 3D system to study the complex tumor stroma interactions driving progression and determining chemio-resistance.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27177201     DOI: 10.3892/ijo.2016.3513

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution.

Authors:  Maria E Monberg; Heather Geiger; Jaewon J Lee; Roshan Sharma; Alexander Semaan; Vincent Bernard; Justin Wong; Fang Wang; Shaoheng Liang; Daniel B Swartzlander; Bret M Stephens; Matthew H G Katz; Ken Chen; Nicolas Robine; Paola A Guerrero; Anirban Maitra
Journal:  Nat Commun       Date:  2022-06-25       Impact factor: 17.694

2.  Oxygen-Carrying Polymer Nanoconstructs for Radiodynamic Therapy of Deep Hypoxic Malignant Tumors.

Authors:  Sandhya Clement; Anna Guller; Saabah B Mahbub; Ewa M Goldys
Journal:  Biomedicines       Date:  2021-03-22

3.  A 3D bioinspired highly porous polymeric scaffolding system for in vitro simulation of pancreatic ductal adenocarcinoma.

Authors:  Stella Totti; Mark C Allenby; Susana Brito Dos Santos; Athanasios Mantalaris; Eirini G Velliou
Journal:  RSC Adv       Date:  2018-06-07       Impact factor: 4.036

4.  Cancer Associated Fibroblast (CAF) Regulation of PDAC Parenchymal (CPC) and CSC Phenotypes Is Modulated by ECM Composition.

Authors:  Stefania Cannone; Maria Raffaella Greco; Tiago M A Carvalho; Helene Guizouarn; Olivier Soriani; Daria Di Molfetta; Richard Tomasini; Katrine Zeeberg; Stephan Joel Reshkin; Rosa Angela Cardone
Journal:  Cancers (Basel)       Date:  2022-07-31       Impact factor: 6.575

5.  RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.

Authors:  Qiu Tu; Xiuyun Liu; Xiaoqing Yao; Ruixue Li; Gaojing Liu; Honglv Jiang; Kaiqin Li; Qiongfang Chen; Xiaoyan Huang; Qing Chang; Guoqiang Xu; Hong Zhu; Peng Shi; Bo Zhao
Journal:  J Exp Clin Cancer Res       Date:  2022-09-15

Review 6.  E-Cadherin in Pancreatic Ductal Adenocarcinoma: A Multifaceted Actor during EMT.

Authors:  Michele Sommariva; Nicoletta Gagliano
Journal:  Cells       Date:  2020-04-22       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.